Introduction
Non-Hodgkin's lymphoma is the most common blood cancer in USA with >72,000 people estimated to be diagnosed in 2016; >20,000 will die of this disease. 1 Our group has had a long-standing interest and track record in developing and evaluating different anti-B-cell lymphoma 2 (anti-BCL-2) strategies including small molecule inhibitors [2] [3] [4] [5] and antisense oligonucleotides. 6, 7 More recently, we have reported DNA interference (DNAi) as a new strategy for cancer therapy. 8, 9 DNAi represents nucleic acid based drugs that block transcription of specific genes involved in complex diseases such as cancer. PNT2258 is a BCL-2-targeting DNAi molecule which contains a single stranded sequence of 24 bases of unmodified phosphodiester DNA (known as PNT100) with a specific sequence, 5′-CACGCACGCGCATCCCCGCCCGTG-3′. PNT100 was designed to hybridize with genomic sequences that reside within the 5′-untranscribed submit your manuscript | www.dovepress.com
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Ebrahim et al regulatory region of the BCL-2 gene to block its transcription via DNAi. The drug was evaluated in preclinical models of lymphoma and prostate cancer 8 and has undergone a Phase I clinical trial. 10 We recently demonstrated that PNT2258 significantly and dose-dependently inhibited BCL-2 at the promoter, RNA, and protein expression levels thus causing apoptosis. 9 Expression of other BCL-2 family members, BCL-xL, BAX, BAK, and BID, was unaffected. Interestingly, PNT2258 also induced S-phase arrest although BCL-2 is not involved in cell cycle regulation. This observation suggested that PNT2258 might silence other unintended genes (off-target effects). In fact, a Basic Local Alignment Search Tool (BLAST) search revealed that promoter sequences for a number of genes were partially homologous (13-16 out of 24 bases) with PNT100 sequences. In this report, we focus on cyclin-dependent kinase-4 (CDK4) gene as a primary unintended target given its roles in cell cycle regulation as a key regulator of the G 1 -S transition. We used three lymphoma cell lines with distinct genetic characteristics to investigate the unintended gene effect of PNT2258 and its role as DNAi. Our results show significant downregulation of CDK4 promoter activity and protein expression following PNT2258 exposure in Wayne State University (WSU)-follicular small cleaved cell lymphoma (FSCCL) and WSU-Waldenström's macroglobulinemia (WM) cells.
Methods and materials
Cell culture
The cell lines used in this study were WSU-FSCCL, WSUdiffuse large cell lymphoma (DLCL2), and WSU-WM, which were established in our laboratory at Wayne State University (WSU).
11-13 WSU-FSCCL (t(14;18) translocation for BCL-2 and t(8;11) c-MYC rearrangements), WSU-DLCL2 (t(14;18) BCL-2 rearrangement), and WSU-Waldenstrom's macroglobulinemia (WM; t(8;14) c-MYC rearrangement). All cell lines are Epstein-Barr virus negative and grow in liquid culture as previously described.
14 The molecular characterization, translocations, and breakpoints of each cell line have been published. 11 Human K562 cell line was obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and cells were maintained according to a standard protocol.
Algorithm
"BLAST 2 SEQUENCES" is an interactive tool that utilizes the BLAST engine for pairwise DNA-DNA or proteinprotein sequence comparison and is based on the same algorithm and statistics of local alignments that have been described earlier. 15 The BLAST 2.0 algorithm generates a gapped alignment by using dynamic programming to extend the central pair of aligned residues. The heuristic methods confine the alignments to a predefined region of the path graph. A performance evaluation of the new gapped BLAST algorithm and its comparison to that of the original ungapped BLAST has been presented. 16 
Luciferase assay
The 404-bp fragment, containing the CDK4 promoter subcloned into pGL3-basic luciferase expression vector (Promega, Madison, WI, USA), was a kind gift of Dr Gary L Firestone (Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA). All transfections were carried out in 24-well plates. Briefly, plasmids (1 μg CDK4 promoter construct, 0.1 μg Renilla luciferase expressing reporter vector pRL-Null [Promega]), were introduced into <50% confluent K562 cells with Lipofectamine® LTX transfection reagent (Life Technologies, Grand Island, NY, USA). The CDK4 and control empty vectors were transfected into K562 cells at a density of 0.2×10 6 viable cells/mL per well in a 24-well plate. Twentyfour hours after transfection, cells were treated with 2.5 μM PNT2258 for 48 hours. Cells were lysed 48 hours later, and promoter activity analyzed in a MicroLumat Plus LB96V reader ( Berthold Technologies, Bad Wildbad, Germany) using the Dual Luciferase® Reporter Assay System (Promega). The firefly luciferase values were normalized to those of Renilla luciferase; all transfections were repeated at least three times.
Antibodies and reagents
CDK4 antibody (DCS-35: sc-23896, 1:500) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA) and the actin antibody (ACTN05, 1:2,000) from Thermo Fisher Scientific (Waltham, MA, USA). Protein concentrations were determined using the micro bicinchoninic acid protein assay (Pierce Chemical Company, Rockford, IL, USA). PNT2258 and associated reagents were provided by ProNAi Therapeutics (Plymouth, MI, USA). The drug PNT2258 consists of a 24 base unmodified DNA phosphodiester oligonucleotide encapsulated in amphoteric proprietary liposomes as previously described. 8 Immunoblotting PNT2258-treated and untreated cells were harvested, washed in phosphate-buffered saline, and lysed in M-PER lysis buffer containing a protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). 9 Equal amounts of protein lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by blotting with the indicated antibod- 
Data analysis and statistical significance
Statistics were conducted using GraphPad Prism 5.0 for Windows (GraphPad Software, Inc, La Jolla, CA, USA) and tests were done with one-way analysis of variance (*P<0.05, **P<0.01, ***P<0.001). P-values <0.05 were considered to be statistically significant. Results are displayed as averages with error bars indicating standard deviations. ImageJ (National Institute of Mental Health, Bethesda, MD, USA) densitometry software was used for quantification of Western blot bands. Selected bands were quantified based on their relative integrated intensities, calculated as the product of the selected pixel area and the mean gray value for those pixels normalized to the internal control.
Results
BLAST search identifies multiple targets for the PNT2258 DNAi oligonucleotides
The BLAST homology search showed that PNT100 does fully bind to the BCL-2 gene as predicted. However, portions of PNT100 sequence averaging 13-14 bases showed 100% identity with four different genes: CDK4, insulin-like growth factor-1 receptor (IGF-1R), p21-activated kinase 3, and transferrin receptor (TFRC/CD71). As expected, CDK4, IGF-1R, and TFRC are involved in cell cycle regulation. CDK4, IGF-1R, and TFRC may also modulate cell cycle/cell death via effects on cell metabolism. Specifically, there was 100% homology in 14 bases (8-21) between PNT100 and CDK4 (Figure 1 ) which is the subject of this report.
PNT2258 represses the CDK4 promoter
We have previously reported that the 24 bases PNT100 sequence included within PNT2258 is complementary to a segment of the consensus sequence recognized by the Sp1 transcription factor in the BCL-2 P1 promoter. 9 To examine whether a putative region in the CDK4 promoter confers PNT2258 responsiveness, we transiently transfected K562 cells with a plasmid containing a 404-bp long CDK4 promoter construct before exposure to PNT2258 for 48 hours. As shown in Figure 2 , PNT2258 strongly downregulated CDK4 promoter activity.
PNT2258 downregulates CDK4 protein in lymphoma cells
We examined whether PNT2258 inhibits CDK4 expression in lymphoma cells. Western blot analysis revealed that CDK4 Homo sapiens B-cell CLL/lymphoma 2 (BCL2), RefSeqGene on chromosome 18
BCL-2 CDK4
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Ebrahim et al protein levels were significantly decreased 24 through 72 hours following exposure to 2.5 μM PNT2258 in WSU-FSCCL and WSU-WM cells ( Figure 3A and B) . However, the CDK4 protein levels in WSU-DLCL2 cells were lower at 48-72 hours, but were not statistically significant ( Figure 3C ).
Discussion
WSU-FSCCL, WSU-DLCL2, and WSU-WM cells were used in a previous study as tools to investigate the effect of PNT2258 in vitro at different concentrations (2.5, 5.0, and 10 μM) on cell growth and survival. PNT2258 induced apoptosis which can be explained by its effect on BCL-2 expression. 9 A significant decrease in cell viability was observed after 48 hours in all of the cell lines exposed to PNT2258 at the lowest concentration (2.5 μM). 9, 17 Nevertheless, PNT2258 has additional effects on WSU-FSCCL cells, such as cell cycle arrest, that cannot be explained by BCL-2 targeting. 18 Results of the present study suggest a broader mechanism of action for DNAi targeting both intended (BCL-2) and unintended (CDK4) genes. Such an effect can enhance the DNAi anticancer effectiveness.
Our findings in this study have two implications: 1) PNT2258 inhibits the expression of CDK4 (which is one of the mechanisms of action of PNT2258 not previously 
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Unintended target effect of anti-BCL-2 DNAi recognized or predicted), and 2) decreased expression of CDK4 explains the previously observed effect of PNT2258 on cell cycle, a finding that cannot be explained by the effect of PNT2258 on the target gene (BCL-2).
Our previous findings suggest that BCL-2 family member MCL-1 protein levels were lower in PNT2258-treated cells. 9 However, we believe that this decrease might be due to knocking down the unintended target gene CDK4, which may lead to a cell cycle arrest induced by PNT2258. MCL-1 downregulation was recently shown to be associated with G 1 /S transition. 19 Moreover, it is not clear if complete 24 bases of DNAi against CDK4 will have a more significant knockdown of CDK4 expression compared with partial homology of PNT100 sequence. CDK4 has been a target for cancer therapy with recent US Food and Drug Administration approval of CDK4/6 inhibitors palbociclib (PD-0332991) and ribociclib (LEE011) for breast cancer. 20, 21 Inhibition of CDK4, IGF-1R, and TFRC leads to decreased proliferation and G 1 cycle arrest. [22] [23] [24] IGF-1R can regulate cell cycle progression at several steps by facilitating G 0 -G 1 transition through p70 S6K and promoting G 1 -S transition by increasing cyclin D1 and CDK4 gene expression. Since activation of IGF-1R and TFRC enhances reactive oxygen species, their inhibition improves mitochondrial function and lowers intrinsic apoptosis, reducing cytochrome c release and increasing caspase-3 and poly(ADP-ribose) polymerase cleavage. [22] [23] [24] These proapoptotic effects are consistent with similar effects of PNT2258 and, although awaiting experimental evidence, suggest that the latter's unintended effects on CDK4, IGF-1R, and TFRC are unlikely to result in harmful "off-target" effects.
Additional investigations are required to explore CDK4 targeting by DNAi as an alternative anti-CDK4 strategy. There remains the possibility of additional unintended target genes for PNT2258 that may also play a significant role as part of its broad mechanism of action.
Conclusion
In our study, we demonstrated that DNAi may work not only through knocking down their intended gene, but also by knocking down other genes. These possibilities should be kept in mind as new DNAi agents are developed.
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